{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:10:32Z","timestamp":1790014232354,"version":"4.0.1"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacasi.2026.08.009","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:38:57Z","timestamp":1789789137000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["HFpEF in Asia\u2014Clinical Characterization and Therapeutic Strategies"],"prefix":"10.1016","author":[{"given":"Jasper","family":"Tromp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiew-Hwa Katherine","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Ting","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8256-902X","authenticated-orcid":false,"given":"Chanchal","family":"Chandramouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7582-7171","authenticated-orcid":false,"given":"Gabriele G.","family":"Schiattarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-0018","authenticated-orcid":false,"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacasi.2026.08.009_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jacasi.2024.01.013","article-title":"Epidemiology and burden of heart failure in Asia","volume":"4","author":"Feng","year":"2024","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacasi.2026.08.009_bib2","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2214-109X(20)30004-8","article-title":"Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study","volume":"8","author":"Tromp","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jacasi.2026.08.009_bib3","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1002\/j.2040-4603.2022.tb00233.x","article-title":"Aging and heart failure with preserved ejection fraction","volume":"12","author":"Larson","year":"2022","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib4","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(25)01393-5","article-title":"Prioritising the primary prevention of heart failure","volume":"406","author":"Khan","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2026.08.009_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jchf.2018.05.018","article-title":"The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF","volume":"6","author":"Savji","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002916","article-title":"Association of obesity with heart failure outcomes in 11 Asian regions: a cohort study","volume":"16","author":"Chandramouli","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib7","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jacc.2025.08.005","article-title":"Beyond adiposity: embracing complexity in diabetes-associated HFpEF","volume":"86","author":"Krumholz","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib8","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1093\/cvr\/cvac179","article-title":"Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions","volume":"118","author":"Peters","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacasi.2026.08.009_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012199","article-title":"Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: outcomes in the ASIAN-HF registry","volume":"9","author":"MacDonald","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2026.08.009_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ejhf.1227","article-title":"Heart failure with preserved ejection fraction in Asia","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3904\/kjim.2023.288","article-title":"Sex differences in clinical characteristics and long-term outcome in patients with heart failure: data from the KorAHF registry","volume":"39","author":"Kim","year":"2024","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018574","article-title":"Sex differences in heart failure with preserved ejection fraction","volume":"10","author":"Sotomi","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2026.08.009_bib13","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/ejhf.2654","article-title":"Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database-Heart Failure Center Registry","volume":"24","author":"Cai","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jchf.2016.09.015","article-title":"Prevalence and clinical significance of diabetes in Asian versus white patients with heart failure","volume":"5","author":"Bank","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ejhf.2156","article-title":"Epicardial fat in heart failure with reduced vs preserved ejection fraction","volume":"23","author":"Tromp","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib16","article-title":"Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry","volume":"15","author":"Tromp","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11897-023-00585-2","article-title":"Heart failure and multimorbidity in Asia","volume":"20","author":"Ang","year":"2023","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jacasi.2026.08.009_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib20","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.08.009_bib21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.009_bib22","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/ejhf.1851","article-title":"Heart failure with preserved ejection fraction diagnostic scores in an Asian population","volume":"22","author":"Ouwerkerk","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40119-024-00367-4","article-title":"Management of heart failure in a resource-limited setting: expert opinion from India","volume":"13","author":"Jain","year":"2024","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.jacasi.2026.08.009_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-090658","article-title":"Adherence to guidelines for natriuretic peptide testing in heart failure: a nationwide survey of healthcare professionals in Vietnam","volume":"15","author":"Do","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacasi.2026.08.009_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2024-002935","article-title":"Recovery of cardiovascular testing in Asia during the COVID-19 pandemic: findings from the INCAPS COVID 2 study","volume":"12","author":"Dai","year":"2025","journal-title":"Open Heart"},{"key":"10.1016\/j.jacasi.2026.08.009_bib27","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.15420\/japsc.2023.07","article-title":"Unearthing gaps in the heart failure ecosystem: an Asian Pacific Society of Cardiology online survey","volume":"2","author":"Lin","year":"2023","journal-title":"J Asian Pac Soc Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib28","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib32","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2026.08.009_bib33","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamacardio.2022.0161","article-title":"Improving enrollment of underrepresented racial and ethnic populations in heart failure trials: a call to action from the heart failure collaboratory","volume":"7","author":"Defilippis","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib34","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/CIRCULATIONAHA.119.041818","article-title":"Deliberating the diagnostic dilemma of HFpEF","volume":"142","author":"Ho","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.009_bib35","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.08.009_bib36","first-page":"E895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.009_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4070\/kcj.2023.0046","article-title":"Korean Society of Heart Failure Guidelines for the management of heart failure: definition and diagnosis","volume":"53","author":"Cho","year":"2023","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jacasi.2026.08.009_bib38","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.cardfail.2025.02.014","article-title":"JCS\/JHFS 2025 Guideline on diagnosis and treatment of heart failure","volume":"31","author":"Kitai","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib39","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.15420\/japsc.2022.42","article-title":"Asian Pacific Society of Cardiology consensus statements on the diagnosis and management of chronic heart failure","volume":"2","author":"Sim","year":"2023","journal-title":"J Asian Pac Soc Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib40","first-page":"760","article-title":"[Chinese guidelines for the diagnosis and treatment of heart failure 2018]","volume":"46","year":"2018","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"10.1016\/j.jacasi.2026.08.009_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocmr.2023.100001","article-title":"Ethnic differences in cardiac structure and function assessed by MRI in healthy South Asian and White European people: a UK Biobank study","volume":"26","author":"Parke","year":"2024","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jacasi.2026.08.009_bib42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.cardfail.2024.08.042","article-title":"Racial differences of cardiac structure and function in heart failure with preserved ejection fraction","volume":"31","author":"Sorimachi","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib43","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcmg.2015.02.014","article-title":"Ethnic-specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL study","volume":"8","author":"Poppe","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacasi.2026.08.009_bib44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.echo.2021.12.004","article-title":"Normal values of left ventricular size and function on three-dimensional echocardiography: results of the world alliance societies of echocardiography study","volume":"35","author":"Addetia","year":"2022","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacasi.2026.08.009_bib45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cardfail.2011.09.003","article-title":"Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific)","volume":"18","author":"Atherton","year":"2012","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijcard.2021.08.001","article-title":"Performance of the H2FPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: a report from the Japanese multicenter registry","volume":"342","author":"Tada","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jjcc.2026.01.014","article-title":"Early diagnosis of heart failure with preserved ejection fraction: from primary care screening to invasive hemodynamic confirmation","volume":"87","author":"Harada","year":"2026","journal-title":"J Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib48","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.009_bib49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ejhf.612","article-title":"Superior performance of N-terminal pro brain natriuretic peptide for diagnosis of acute decompensated heart failure in an Asian compared with a western setting","volume":"19","author":"Ibrahim","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ehf2.12252","article-title":"N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure","volume":"5","author":"Tromp","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib51","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.15420\/japsc.2024.48","article-title":"Real-world management of heart failure in the Philippines: the HF ER registry","volume":"4","author":"Reyes","year":"2025","journal-title":"J Asian Pac Soc Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib52","article-title":"Machine learning algorithms to predict heart failure with preserved ejection fraction among patients with premature myocardial infarction","volume":"12","author":"Wang","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101040","article-title":"A machine learning-derived score to effectively identify heart failure with preserved ejection fraction","volume":"3","author":"Bermea","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacasi.2026.08.009_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmedinf.2024.105703","article-title":"Development and validation of a machine learning model to predict the risk of readmission within one year in HFpEF patients: short title: prediction of HFpEF readmission","volume":"194","author":"Hu","year":"2025","journal-title":"Int J Med Inform"},{"key":"10.1016\/j.jacasi.2026.08.009_bib55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12967-021-02735-3","article-title":"Biomarker profiling for risk of future heart failure (HFpEF) development","volume":"19","author":"Watson","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib56","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jacc.2018.11.060","article-title":"Combining circulating MicroRNA and NT-proBNP to detect and categorize heart failure subtypes","volume":"73","author":"Wong","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41591-018-0240-2","article-title":"Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram","volume":"25","author":"Attia","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib58","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41746-023-00993-7","article-title":"Artificial intelligence-enabled ECG for left ventricular diastolic function and filling pressure","volume":"7","author":"Lee","year":"2024","journal-title":"NPJ Digital Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib59","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/ehjdh\/ztab081","article-title":"Deep learning detects heart failure with preserved ejection fraction using a baseline electrocardiogram","volume":"2","author":"Unterhuber","year":"2021","journal-title":"Eur Heart J Digit Health"},{"key":"10.1016\/j.jacasi.2026.08.009_bib60","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ehjdh\/ztaa015","article-title":"Artificial intelligence assessment for early detection of heart failure with preserved ejection fraction based on electrocardiographic features","volume":"2","author":"Kwon","year":"2020","journal-title":"Eur Heart J Digit Health"},{"key":"10.1016\/j.jacasi.2026.08.009_bib61","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/ehjdh\/ztaf080","article-title":"Artificial intelligence-enabled electrocardiogram model for predicting heart failure with preserved ejection fraction: a single-center study","volume":"6","author":"Hong","year":"2025","journal-title":"Eur Heart J Digit Health"},{"key":"10.1016\/j.jacasi.2026.08.009_bib62","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2589-7500(21)00235-1","article-title":"Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study","volume":"4","author":"Tromp","year":"2022","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.jacasi.2026.08.009_bib63","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1038\/s41467-025-58283-7","article-title":"External validation of artificial intelligence for detection of heart failure with preserved ejection fraction","volume":"16","author":"Akerman","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacasi.2026.08.009_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100452","article-title":"Automated echocardiographic detection of heart failure with preserved ejection fraction using artificial intelligence","volume":"2","author":"Akerman","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacasi.2026.08.009_bib65","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.echo.2024.06.016","article-title":"Automated echocardiographic detection of heart failure with preserved ejection fraction using artificial intelligence is associated with cardiac mortality and heart failure hospitalization","volume":"37","author":"Cassianni","year":"2024","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacasi.2026.08.009_bib66","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1038\/s41467-022-34245-1","article-title":"A formal validation of a deep learning-based automated workflow for the interpretation of the echocardiogram","volume":"13","author":"Tromp","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacasi.2026.08.009_bib67","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jcmg.2021.05.005","article-title":"AI-assisted echocardiographic prescreening of heart failure with preserved ejection fraction on the basis of intrabeat dynamics","volume":"14","author":"Chiou","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacasi.2026.08.009_bib68","first-page":"913","article-title":"CardioMEMS heart sensor allows monitoring of pressures to improve outcomes in NYHA class III heart failure patients (CHAMPION) trial: impact of hemodynamic guided care on patients with preserved ejection fraction","volume":"16","author":"Adamson","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib69","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2022.08.012","article-title":"Hemodynamically-guided management of heart failure across the ejection fraction spectrum: the GUIDE-HF trial","volume":"10","author":"Zile","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib70","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jchf.2016.12.011","article-title":"A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study","volume":"5","author":"Boehmer","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004669","article-title":"HeartLogic multisensor algorithm identifies patients during periods of significantly increased risk of heart failure events: results from the MultiSENSE study","volume":"11","author":"Gardner","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib72","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/joa3.12913","article-title":"HeartLogic multisensor algorithm response prior to ventricular arrhythmia events","volume":"39","author":"Kataoka","year":"2023","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jacasi.2026.08.009_bib73","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cardfail.2025.09.007","article-title":"Current and future landscape of remote hemodynamic monitoring","volume":"31","author":"Klein","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib74","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1038\/s41591-022-02053-1","article-title":"Prospective evaluation of smartwatch-enabled detection of left ventricular dysfunction","volume":"28","author":"Attia","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib75","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2026.08.009_bib76","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib77","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib78","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib79","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jchf.2023.03.011","article-title":"How to manage heart failure with preserved ejection fraction: practical guidance for clinicians","volume":"11","author":"Desai","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib80","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.jacc.2016.08.048","article-title":"Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins","volume":"68","author":"Kotecha","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib81","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.amjcard.2019.08.018","article-title":"Prevalence and incidence of atrial fibrillation in ambulatory patients with heart failure","volume":"124","author":"Pellicori","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib82","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jacc.2023.12.033","article-title":"Implications of atrial fibrillation for guideline-directed therapy in patients with heart failure: JACC state-of-the-art review","volume":"83","author":"Newman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib83","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/ehf2.12696","article-title":"Ethnic differences in atrial fibrillation among patients with heart failure in Asia","volume":"7","author":"Tan","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib84","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jacasi.2023.06.007","article-title":"Clinical features of heart failure with normal ejection fraction: insights from the ASIAN-HF registry","volume":"3","author":"Teramoto","year":"2023","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacasi.2026.08.009_bib85","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","article-title":"Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation","volume":"76","author":"Reddy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib86","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jacc.2015.03.043","article-title":"Patient selection in heart failure with preserved ejection fraction clinical trials","volume":"65","author":"Kelly","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib87","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jchf.2018.06.006","article-title":"Fat, Female, fatigued: features of the obese HFpEF phenotype","volume":"6","author":"Lam","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.743327","article-title":"The \u201cObesity Paradox\u201d in patients with HFpEF with or without comorbid atrial fibrillation","volume":"8","author":"Guo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib89","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/risa.14195","article-title":"Risk modelling of ESG (environmental, social, and governance), healthcare, and financial sectors","volume":"45","author":"Chaudhry","year":"2025","journal-title":"Risk Anal"},{"key":"10.1016\/j.jacasi.2026.08.009_bib90","doi-asserted-by":"crossref","first-page":"E984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.009_bib91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12872-021-02080-9","article-title":"Waist to height ratio is associated with an increased risk of mortality in Chinese patients with heart failure with preserved ejection fraction","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacasi.2026.08.009_bib92","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jacasi.2025.07.017","article-title":"Obesity-related Asian patients with heart failure with preserved ejection fraction","volume":"5","author":"Kagami","year":"2025","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacasi.2026.08.009_bib93","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.009_bib94","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","article-title":"Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review","volume":"73","author":"McHugh","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib95","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013114","article-title":"Association of diabetes mellitus on cardiac remodeling, quality of life, and clinical outcomes in heart failure with reduced and preserved ejection fraction","volume":"8","author":"Yap","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2026.08.009_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132748","article-title":"A systematic review of multimorbidity clusters in heart failure: effects of methodologies","volume":"420","author":"Kaur","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib97","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.amjcard.2025.10.013","article-title":"Heart failure with preserved ejection fraction and chronic kidney disease: from pathophysiology to treatment","volume":"258","author":"Grilo","year":"2026","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib98","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3389\/fphys.2019.01108","article-title":"Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets","volume":"10","author":"van de Wouw","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib99","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/ehf2.13221","article-title":"Hospital readmissions of patients with heart failure from real world: timing and associated risk factors","volume":"8","author":"Wideqvist","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib100","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jacc.2023.05.040","article-title":"Global comparison of readmission rates for patients with heart failure","volume":"82","author":"Foroutan","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064997","article-title":"Clinical characteristics and mortality of patients with heart failure in Southern Sweden from 2013 to 2019: a population-based cohort study","volume":"12","author":"Davidge","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacasi.2026.08.009_bib102","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0336809","article-title":"Predicting 30-day and 1-year mortality in heart failure with preserved ejection fraction (HFpEF)","volume":"20","author":"Shin","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jacasi.2026.08.009_bib104","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib106","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib107","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","article-title":"Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.08.009_bib108","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.08.009_bib109","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jchf.2021.05.009","article-title":"Advanced heart failure epidemiology and outcomes: a population-based study","volume":"9","author":"Dunlay","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib110","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1016\/S2468-2667(24)00215-9","article-title":"Contemporary epidemiology of hospitalised heart failure with reduced versus preserved ejection fraction in England: a retrospective, cohort study of whole-population electronic health records","volume":"9","author":"Fletcher","year":"2024","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.jacasi.2026.08.009_bib111","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007901","article-title":"Global differences in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"14","author":"Tromp","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib112","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021414","article-title":"Readmissions, death and its associated predictors in heart failure with preserved versus reduced ejection fraction","volume":"10","author":"Tay","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2026.08.009_bib113","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib114","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1253\/circj.CJ-18-0073","article-title":"Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction - a report from the Japanese heart failure syndrome with preserved ejection fraction (JASPER) registry","volume":"82","author":"Nagai","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jacasi.2026.08.009_bib115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2015.01.063","article-title":"Predictors of two-year mortality in Asian patients with heart failure and preserved ejection fraction","volume":"183","author":"Yap","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib116","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/eurjhf\/hft062","article-title":"How do patients with heart failure with preserved ejection fraction die?","volume":"15","author":"Chan","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib117","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacc.2016.10.078","article-title":"Mode of death in heart failure with preserved ejection fraction","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib118","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4296","article-title":"Mode of death among Japanese adults with heart failure with preserved, midrange, and reduced ejection fraction","volume":"3","author":"Kitai","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacasi.2026.08.009_bib119","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013441","article-title":"Noncardiac versus cardiac mortality in heart failure with preserved, midrange, and reduced ejection fraction","volume":"8","author":"Vergaro","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2026.08.009_bib120","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1161\/CIRCHEARTFAILURE.121.008597","article-title":"Mode of death in patients with heart failure and preserved ejection fraction: insights from PARAGON-HF trial","volume":"14","author":"Desai","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib121","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/eurjhf\/hfr072","article-title":"Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction","volume":"13","author":"Hoekstra","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib122","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jacasi.2023.03.015","article-title":"Patient-reported status and heart failure outcomes in Asia by sex, ethnicity, and socioeconomic status","volume":"3","author":"Lawson","year":"2023","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacasi.2026.08.009_bib123","doi-asserted-by":"crossref","first-page":"13593","DOI":"10.3390\/ijerph192013593","article-title":"Symptom burden among hospitalised older patients with heart failure in Hanoi, Vietnam","volume":"19","author":"Nguyen","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jacasi.2026.08.009_bib124","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ahj.2017.06.016","article-title":"Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure","volume":"191","author":"Luo","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacasi.2026.08.009_bib125","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/clc.23394","article-title":"Ethnic differences in quality of life and its association with survival in patients with heart failure","volume":"43","author":"Stein","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib126","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/JCN.0000000000000951","article-title":"Gender differences in anxiety, depression, insomnia, and quality of life in heart failure with preserved ejection fraction: a multicenter, cross-sectional study","volume":"38","author":"Yang","year":"2023","journal-title":"J Cardiovasc Nurs"},{"key":"10.1016\/j.jacasi.2026.08.009_bib127","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.08.009_bib128","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2026.08.009_bib129","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib130","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib131","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib132","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.jchf.2024.04.027","article-title":"Low natriuretic peptide levels and outcomes in patients with heart failure and preserved ejection fraction","volume":"12","author":"Kondo","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib133","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s00392-020-01632-x","article-title":"Covariate adjusted reanalysis of the I-preserve trial","volume":"109","author":"Ferreira","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib134","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT \u2014 new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib135","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jacbts.2016.03.001","article-title":"Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations","volume":"1","author":"Bristow","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacasi.2026.08.009_bib136","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.009_bib137","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.009_bib138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib139","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.08.009_bib140","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41591-022-02041-5","article-title":"Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-preserved","volume":"28","author":"Anker","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib141","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1093\/eurheartj\/ehab360","article-title":"Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial","volume":"42","author":"Lam","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.08.009_bib142","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jacasi.2023.10.005","article-title":"Effects of dapagliflozin in patients in Asia: a post hoc subgroup analysis from the DELIVER trial","volume":"4","author":"Wang","year":"2024","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacasi.2026.08.009_bib143","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib144","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2023.05.056","article-title":"Efficacy of dapagliflozin according to geographic location of patients with heart failure","volume":"82","author":"Kondo","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib145","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jdi.13959","article-title":"Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: results from the EMPRISE study","volume":"14","author":"Kim","year":"2023","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jacasi.2026.08.009_bib146","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000545626","article-title":"Increasing prescription of SGLT2 inhibitors with expanded indications to the elderly population in Japan","volume":"11","author":"Oda","year":"2025","journal-title":"Kidney Dis"},{"key":"10.1016\/j.jacasi.2026.08.009_bib147","article-title":"Cost-utility analysis of add-on SGLT2 inhibitors for heart failure with reduced ejection fraction in India","volume":"14","author":"Sasidharan","year":"2025","journal-title":"Health Pol Technol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib148","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s41669-024-00526-2","article-title":"Cost-utility and budget impact analysis of adding SGLT-2 inhibitors to standard treatment in type 2 diabetes patients with heart failure: utilizing national database insights from Thailand","volume":"9","author":"Kongmalai","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.jacasi.2026.08.009_bib149","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.3474","article-title":"Estimated sustainable cost-based prices for diabetes medicines","volume":"7","author":"Barber","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacasi.2026.08.009_bib150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S2213-8587(21)00322-3","article-title":"Diabetes and the WHO model list of essential medicines","volume":"10","author":"Danne","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib151","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.009_bib152","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamacardio.2024.4613","article-title":"Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Chimura","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib153","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.009_bib154","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib155","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists across geographical regions in heart failure: a patient-level pooled analysis","volume":"28","author":"Chimura","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib156","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib157","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.009_bib159","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide vs placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2026.08.009_bib161","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.009_bib162","doi-asserted-by":"crossref","first-page":"e1874","DOI":"10.1016\/S2214-109X(23)00408-4","article-title":"Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study","volume":"11","author":"Gerhardt","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jacasi.2026.08.009_bib163","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","article-title":"Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial","volume":"146","author":"Butt","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.009_bib164","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080","article-title":"Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial","volume":"15","author":"Peikert","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacasi.2026.08.009_bib165","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1016\/S2214-109X(17)30196-1","article-title":"Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study","volume":"5","author":"Dokainish","year":"2017","journal-title":"Lancet Glob Health"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726007088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726007088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:39:53Z","timestamp":1790012393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374726007088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":161,"alternative-id":["S2772374726007088"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.08.009","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HFpEF in Asia\u2014Clinical Characterization and Therapeutic Strategies","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}